Understanding the financial burden that will be imposed by a new health technology on the health system is important for planning and budgeting.

Dihydroartemisinin–piperaquine is relatively more expensive than artemether–lumefantrine but has a greater potential to reduce the burden of Plasmodium falciparum malaria when used as the first-line drug to treat uncomplicated malaria.